2025, Adverse Reactions and Labelling

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

LifeProNow

FEBRUARY 2, 2025

January 30, 2025: “The U.S. The most common adverse reactions in study participants who received Journavx were itching, muscle spasms, increased blood level of creatine phosphokinase, and rash.

Adverse Reactions

Adverse Reactions Labelling Drug Development

FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment

Express Pharma

JANUARY 15, 2025

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date for August 31, 2025. The BLA submission is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modelling of observed data. Eisai holds final decision-making authority.

Adverse Reactions

Adverse Reactions Labelling Hospitals

9 Sneaky Thyroid Toxins Hiding in Your Home

The Thyroid Pharmacist

MARCH 7, 2025

to fluoride in my tap water, to hidden mold in my home, to my shampoo and deodorant (have you ever read those labels?!), 16] Even more concerning, of the 133 different VOCs found across all tested products, only one, ethanol, was actually listed on any label! From indoor pollutants like formaldehyde (yes, really!),

Health and Personal Care Stores

Health and Personal Care Stores Labelling Immunity Immunization

Pharmacist Digest

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment

9 Sneaky Thyroid Toxins Hiding in Your Home

Stay Connected